- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors, with potential for expanded therapeutic index - Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025 - Focused prioritization and disciplined capital deployment

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-877

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors ○ VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage observed in 50% (10/20) of participants with various HER2-expressing cancers; confirmed partial responses in 33% (2/6) of participants with HER2-positive CRC ○ VIR-5500: PSA declines in 100% (12/12) and PSA50 response confirmed in 58% (7/12) of mCRPC patients with first step dose ≥120 µg/kg – Promising safety profile with MTD not yet reached for VIR-5818 or VIR-5500 and no dose-limiting cytokine release syndrome (CRS) observed; no CRS greater than grade 2 reported – Initial clinical data de

– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts – – Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares – – Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 – – New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SO

– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting – – Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing recognition of the potential of tobevibart and elebsiran in chronic hepatitis delta – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on t

– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate – – Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® – – Key functional cure data from 24-week follow-up expected in Q2 2025 – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart

– Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 2025 – – Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024 – – The Company will host a Hepatitis Investor Event following AASLD on November 19, 2024 – – Jason O'Byrne appointed as Chief Financial Officer – – Conference call scheduled for October 31, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. "This quarter was transf

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

– Seasoned biotech executive brings decades of effective financial leadership to Vir – Vir Biotechnology Inc. (NASDAQ:VIR) today announced that Jason O'Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O'Byrne will join the Vir Executive Management Team and report directly to the company's Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA. Mr. O'Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operation

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer, effective November 6, 2023. Dr. Towne will be responsible for leading the Company's research function from basic research through scale-up manufacturing and the introduction of drug candidates to clinical trials. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231026830042/en/Jennifer Towne, Ph.D., appointed as Executive Vice President and

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment Company owns exclusive global rights of BRII-693 in development for difficult-to-treat carbapenem-resistant Gram-negative bacterial infections Dr. David Margolis appointed as Chief Medical Officer to lead organization's late-stage clinical programs towards commercialization DURHAM, N.C. and BEIJING, July 5, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company's strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir's corporate social responsibility and environmental, social and governance efforts. She will report to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company's Executive Management Team. "Sasha has an impressive track record as b

SAN FRANCISCO, May 15, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company's business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir's Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir's executive management team. "I am delighted to have the opportunity to work with Jeff again. He brings decades of international healthcare leadership experience to Vir, as well as a track record of accelerating

– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of sotrovimab collaboration revenue recognized in 2022 – – Strong balance sheet expected to fund Vir's robust portfolio through major inflection points with the flexibility to evaluate external opportunities – SAN FRANCISCO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022. "2022 was a seminal year for Vir. We remained on the front lines of the COVID-1

– Experienced biotech executive brings more than 20 years of financial leadership to Vir – – Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition period – SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer (CFO), effective March 27, 2023. The appointment follows the resignation of Howard Horn, who will leave the Company after a brief transition period. "We are delighted to welcome Sung to Vir's executive leadership team. His exceptional track record of driving financial performance, scaling global opera

– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors – SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company's Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Memb

SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global, effective March 2, 2022. Reporting to Vir's Chief Executive Officer George Scangos, Ph.D., and joining Vir's senior leadership team, Friedl-Naderer will be responsible for shaping the company's corporate and portfolio strategy, leading the global commercial organization and driving business development efforts. "Johanna is an experienced commercial executive with an impressive range of global operational expertise and leadership success, and I am thrilled to have the opportu

JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously

BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously

JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously

Goldman upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $53.00 from $41.00 previously

Morgan Stanley upgraded Vir Biotechnology from Underweight to Equal-Weight and set a new price target of $30.00 from $18.00 previously

SVB Leerink initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $40.00

Morgan Stanley initiated coverage of Vir Biotechnology with a rating of Underweight and set a new price target of $15.00

Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously

Robert W. Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously

Robert W. Baird downgraded Vir Biotechnology from Neutral to Underperform and set a new price target of $36.00